Table 3 Summary of outcomes of MR gene mutation patients compared to ELN 2022 risk groups.

From: Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients

 

ELN 2022 favorable

ELN 2022 intermediate

ELN 2022 adverse*

MR gene mutation

EFS

 median

28.1 [22.5–35.8]

8.6 [7.9–9.4]

3.2 [2.9–3.7]

6.8 [5.6–8.1]

 HR

0.42 [0.39–0.46]

1.04 [0.97-1.12]

2.12 [1.98–2.27]

1.34 [1.21–1.47]

 p

<0.001

0.238

<0.001

<0.001

RFS

 median

79.4 [56.4–105.3]

14.4 [12.3–16.4]

9.8 [8.7–11.2]

11.9 [10.1–14.4]

 HR

0.48 [0.44–0.52]

1.15 [1.05–1.26]

1.84 [1.68–2.01]

1.42 [1.26–1.61]

 p

<0.001

0.002

<0.001

<0.001

OS

 median

135.9 [103.2–157.7]

21.5 [18.9–24.3]

11.0 [10.0–12.1]

17.9 [15.7–20.1]

 HR

0.40 [0.37–0.44]

0.99 [0.91–1.07]

2.2 [2.09–2.42]

1.27 [1.14–1.41]

 p

<0.001

0.737

<0.001

<0.001

  1. Survival is reported for the ICC definition of MR gene mutations. Survival times are displayed in months. Square brackets show 95%-confidence intervals. Boldface indicates statistical significance (p < 0.05). All patients in the cohort were retrospectively assigned to ELN 2022 risk groups. For this analysis, patients with MR gene mutation were only considered for the MR gene mutation group if no other class-defining alterations were present. For instance, if a patient was originally only assigned to ELN 2022 adverse risk because of the presence of an MR gene mutation, this patient was allocated to the respective MR gene mutation group. Vice versa, if MR gene mutation bearing patients had co-occurring markers of favorable, intermediate (t(9;11)), or adverse risk, they were allocated to the respective ELN group. Hence, patients in the MR gene mutation group have no other risk-defining markers except for MR gene mutation 3.
Back to article page